Healthcare DIVE November 26, 2024
Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top 10 drugs in global sales — early next year.
Dive Brief:
- Sanofi is joining its fellow drugmakers in trying to put new restrictions on savings sent to hospitals in a federal drug discount program.
- A spokesperson for Sanofi confirmed plans to implement a similar model as those proposed by Johnson & Johnson and Eli Lilly — to give hospitals rebates for eligible drugs in program, called 340B, instead of discounts at the point of purchase — that have faced pushback from federal regulators.
- Sanofi plans to phase in its model for different 340B-eligible providers starting early next year....
Today's Sponsors
Today's Sponsor